Preclinical models for precision oncology.

Area of Science:

• Oncology
• Translational Medicine
• Cancer Research

Background:

• Precision medicine has transformed cancer treatment by tailoring therapies to individual molecular profiles.
• Accurate prediction of treatment efficacy requires robust preclinical models.
• Identifying suitable patient populations for clinical trials is crucial for therapeutic development.

Purpose of the Study:

• To evaluate the extent to which preclinical models recapitulate human tumor features.
• To assess the predictive value of these models for treatment efficacy and clinical benefit.
• To provide examples across different tumor types.

Main Methods:

• Review of existing literature on preclinical cancer models.
• Analysis of studies comparing preclinical models (cell lines, organoids, tumorgrafts) to human tumors.
• Examination of data correlating preclinical model predictions with clinical outcomes.

Main Results:

• Preclinical models exhibit varying degrees of fidelity in recapitulating human tumor characteristics.
• Certain models, like organoids and tumorgrafts, show higher potential for predicting treatment response than traditional cell lines.
• Examples demonstrate the utility and limitations of these models in anticipating therapeutic success.

Conclusions:

• Preclinical models are essential but imperfect tools in precision oncology.
• Model selection should be guided by the specific research question and tumor type.
• Further development is needed to enhance the predictive accuracy of preclinical models for clinical benefit.